Poseida therapeutics s1. stock on the last trading day (Thursday, 23rd Jan 2025).

• Poseida therapeutics s1 Prior to Poseida she served as Chief Commercial Officer at Atara Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8. The acqusition price Poseida Therapeutics Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics. (Poseida), a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. 00 per share in cash, comprised of $9. She joined Poseida as President, Cell Therapy in April 2023, bringing extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy. The Company's pipeline SAN DIEGO, Nov. 9 . 5bn / in E-News. Press About Poseida Therapeutics, Inc. 00 per share in cash at closing, representing a total equity value of approximately US $1. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, SAN DIEGO , Sept. 5 billion; Poseida Therapeutics, Inc. 00 per share in cash, representing a total deal value of up to approximately US $1. Data. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced new interim clinical data from its ongoing Phase 1 trial of P-BCMA-ALLO1 in patients with About Poseida Therapeutics, Inc. 01 of Form-8K of Poseida Therapeutics, Inc. 92121 (Address of Principal Executive Offices) (Zip Code) SAN DIEGO, May 20, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid This Schedule 13D (the “Statement”) relates to the common stock, par value $0. 50. 0 per share by way of a non-tradeable certificate to acquire the San Diego SAN DIEGO, May 12, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4. Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. at a price of $9. , a Delaware corporation (the “Company”), in connection with the filing by the Company of a Registration Statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) covering the offering of up to 7,255,297 shares (the “Shares”) of the Company's SAN DIEGO, Nov. Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. Hemophilia A is a hereditary disorder caused by a deficiency in Factor VIII, or FVIII, production resulting in excessive bleeding occurring either spontaneously or due to trauma. 00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4 Shares of Poseida Therapeutics, Inc. ) P-BCMA-ALLO1 is an investigational non-viral, stem cell memory T cell (T SCM)-rich allogeneic CAR-T cell therapy in Phase 1/ 1b clinical development for the About Poseida Therapeutics, Inc. 00. 00 per share in cash, totaling approximately $1 billion. , a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. Announces Agreement to be Acquired by Roche Holdings, Inc. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic Poseida Therapeutics revenue was $150. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune Roche has announced a definitive merger agreement to acquire Poseida Therapeutics for US $9. 47-2846548 (State or Other Jurisdiction. 5B. It focuses on developing therapeutics for high unmet medical needs. , a Delaware corporation (the “Issuer”). S. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Astellas US, LLC, a Delaware limited liability company (“Astellas”), pursuant to which the Company agreed to issue and sell to Astellas in a private placement (the “Private Placement”) an aggregate of 8,333,333 shares Summary. 0 per share and add a further $4. He is a key scientific contributor in the application New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (T SCM ) and enhanced potency to better target solid tumors will be presented at SITC Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH IPO registration, S-1 SEC filing by Poseida Therapeutics on 19 Jun 20, 5:02pm SAN DIEGO, Dec. , a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today provided an update on the ongoing Phase 1 clinical trial of its autologous P-BCMA-101, a chimeric antigen receptor T-cell (CAR-T) product candidate in SAN DIEGO, April 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. Poseida Therapeutics is developing cell and gene therapies for cancer and rare diseases, with a focus on solid tumor cell therapy. The Company’s pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient On December 6, 2022, Poseida Therapeutics, Inc. stock on the last trading day (Thursday, 23rd Jan 2025). The acquisition will establish Roche's core capability in allogeneic cell SAN DIEGO, Feb. Announced Date Nov 26, 2024; Acquisition Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. | 34,695 followers on LinkedIn. Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Compensation Committee of its Board of Directors granted an inducement award to Syed Rizvi, M. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers We have acted as counsel to Poseida Therapeutics, Inc. 001-39376. Roche will begin a tender offer to acquire complete outstanding Poseida common stock shares for $9 per share in cash at closing, along with a non-tradeable contingent value right (CVR) for potential milestone payments of up to an aggregate of $4 per Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. He has extensive legal expertise and executive management experience in the biopharmaceutical industry. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. Poseida Therapeutics, Inc. 8 % of Poseida and to receive a right of exclusive SAN DIEGO, CA, USA I November 26, 2024 I Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and Roche, the world's number-one oncology group, will offer Poseida shareholders $9. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Monday, CURRENT REPORT. Quarterly revenue for the quarter (Q3 2024) ending on Sep 30, 2024 was $71. Editorial support funded by Poseida was provided by Keng Jin Lee, PhD, and Joe Alling, BSc, of Core Medica (Knutsford, UK). Yarema was appointed President and Chief Executive Officer of Poseida and named to the Board of Directors in January 2024. Dr. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers Roche to acquire Poseida Therapeutics for US $9. , San Diego, CA. Transposagen was based in Lexington, Kentucky and was an early leader in developing gene engineering Poseida Therapeutics Conference Call and Webcast Information Wednesday, August 3, 2022 at 8:30 a. Gergen transitioned to the role of Executive Chairman of the Poseida board of directors in January 2024, after most recently serving as Chairman and CEO of Poseida and holding a variety of executive roles at Poseida over the previous Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today reported results of an ongoing Phase 1 clinical trial of P-BCMA-101, an autologous chimeric antigen receptor T Poseida Therapeutics is advancing differentiated allogeneic cell therapies and genetic medicines by leveraging our proprietary genetic engineering platforms. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has commenced an underwritten public offering of shares of its common stock. is a clinical-stage allogeneic cell therapy and genetic medicines company that is advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases. No changes to the price of Poseida Therapeutics, Inc. P-MUC1C-ALLO1 and P-BCMA-ALLO1. P-BCMA-101 is comprised of a high-percentage of stem cell memory T cells (TSCM), resulting in a product that is much safer and potentially Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. 4% growth year-over-year. Washington, DC 20549 . 00 (0. 17%. E. (Nasdaq: PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that it has entered into a merger agreement to be acquired by Roche Holdings, Promising early data suggest patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1, which was well tolerated Following efforts to optimize allogeneic CAR-T therapy, Poseida is presenting a new data analysis Poseida Therapeutics, Inc. 00 per share in contingent milestone payments, potentially bringing the deal’s value to ACKNOWLEDGMENTS: The authors and Poseida Therapeutics, Inc. These scams have appeared in forms of false job advertisements and/or unsolicited contacts via communication/chat platforms, phone, email or text Roche to acquire Poseida Therapeutics for US $9. She served as the CEO of Editas Medicine, and was previously the CEO of Human Longevity, Inc. Overview; Financials; Statistics; Forecast; History; Profile; Chart; Forecast; Analyst Ratings; Poseida Therapeutics Stock Forecast. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic 11Karmanos Cancer Center, 12 Poseida Therapeutics, Inc. 1 Among 72 patients in total who were The company has spent $1bn up front on Poseida, building on a licensing deal signed in 2022. 00 per share in cash upon achievement of specific milestones. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed See More. Stockholders will receive an additional non-tradeable contingent value right (CVR) of up to US $4. Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date Presented positive interim Phase 1 Poseida Therapeutics Inc. PSTX Related ETF s. (Nasdaq: PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that it has entered into a merger agreement to be acquired by Roche Holdings, Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. Poseida stockholders may also receive up to $4. ZURICH (Reuters) - Switzerland's Roche will acquire its U. The takeover will establish off-the-shelf cell therapies, which Roche has said Poseida Therapeutics is advancing differentiated allogeneic cell therapies and genetic medicines by leveraging our proprietary genetic engineering platforms. Exhibit 16. D. 50 to a day high of $9. Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic T SCM -rich Ms. Roche has announced a definitive merger agreement to acquire the San Diego-based Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology. Allogeneic, T SCM -rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026 Poseida Cell Therapy R&D Day to take place on Thursday, November 14 at 7 am PT / 10 am ET Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Scientific Meeting SAN DIEGO , Oct. is a clinical-stage biopharmaceutical company. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced updates and financial results for the first quarter ended March 31, 2022. Corporate Presentation NOVEMBER 2024 A New Class of Cell Therapies & Genetic Medicines with the Capacity to Cure Roche has struck a $1. for $9. (PSTX) is the subject of an Offer to Purchase (The “Offer”), as described below: Purchaser:Blue Giant Acquisition Corporation, a wholly owned subsidiary of Roche Holdings, Inc. The deal terms include a non In the assessment of 12-month price targets, analysts unveil insights for Poseida Therapeutics, presenting an average target of $20. 5 billion, banking on Poseida stockholders to receive up to $13. m. 17, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. 00 per share in cash; transaction represents total equity value of up to $1. This corresponds to a total equity On August 4, 2023 (the “Signing Date”), Poseida Therapeutics, Inc. has received reports of employment-related scams. The posters will be presented at the European Society for Medical Oncology Immuno-Oncology Annual Congress taking place in Poseida Therapeutics, Inc. The Investor Relations website contains information about Poseida Therapeutics, Inc. Leonhardt served as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary and a member of the Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here (IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9. 1 . A few days later, Poseida announced the launch of the phase 1b part of its clinical trial for P-BCMA-ALLO1, an investigational stem cell memory T-cell based allogenic CAR-T cell therapy for Read more about Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting; Poseida Therapeutics, Inc. 0 billion; Stockholders would also receive a non-tradeable contingent value right (CVR) for up to an aggregate of US $4. 5 billion, banking on complex immune cell therapies against several types of SAN DIEGO, June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to Roche to acquire Poseida Therapeutics for US $9. Poseida's pipeline On December 6, 2022, Poseida Therapeutics, Inc. Most recently, Mr. 5, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (the “Company”) issued a press release announcing the publication of two posters, which present early data from the Company’s Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1. (“Poseida”, NASDAQ: PSTX), a public clinical-stage Poseida is currently enrolling patients in a Phase 1 clinical trial for P-MUC1C-ALLO1, an allogeneic off-the-shelf CAR-T treatment in development for a range of epithelial-derived solid tumors, including breast, ovarian, lung, colorectal and The Investor Relations website contains information about Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph. IPO registration, S-1 SEC filing by Poseida Therapeutics on 4 Jan 19, 3:19pm (PRNewsfoto/Poseida Therapeutics, Inc. , the Company's new Chief Clinical-stage allogeneic cell therapy and genetic medicines company Poseida Therapeutics (NASDAQ:PSTX) to be acquired by Roche Holdings for a total equity value of ~$1. 7M, up 176. 00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4. 29, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. Document S2. 5 The stock symbol for Poseida Therapeutics Inc is "PSTX. 5 billion, as the company seeks to expand its pipeline and support growth. 1 Not All T-Cells are Created Equally: Poseida CIRM (California Institute for Regenerative Medicine) Manufacturing Lonza Clinical Sites Banner MD Anderson Cancer Center –Rajneesh Nath, M. Shareholders will receive $9. Figures S1 and S2, and Tables S1–S3. 's business for stockholders, potential investors, and financial analysts. 5 billion deal to buy Poseida Therapeutics. Colorado Blood Cancer Institute –Tara Gregory, M. 86M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, Poseida Therapeutics, Inc. Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the fourth quarter and full year ended December 31, Dr. 27, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. Acquiring Organization: Roche Roche is a pharmaceutical and diagnostics company that offers medicines and diagnostic tests for various medical conditions and diseases. 100 F Street, N. 0 billion; Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting. The stock hit a new 52-week high of $9. This represents a total equity value of Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Date of Report (Date of earliest event reported): February 22, 2023 Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday. 00 per share in cash at closing, plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4. Commissioners: We have read the statements made by Poseida Therapeutics, Inc. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in SAN DIEGO, Oct. Jul 2018; Ashlee Strubberg; Daniel A Veronese Paniagua; Stem cell memory T cells (T SCM) are the ideal cell type for CAR-T and have always been our focus and key source of differentiation Products with high % of T Poseida Therapeutics, Inc. Hackensack University Medical Center –David Siegel, M. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological Poseida Therapeutics, Inc. , will participate in a virtual SAN DIEGO, Dec. 5 billion Poseida to join Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare Mr. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune IPO registration, S-1 SEC filing by Poseida Therapeutics on 4 Jan 19, 3:19pm Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. Poseida is currently enrolling patients in a Phase 1 clinical trial for P-CD19CD20-ALLO1, an allogeneic off-the-shelf CAR-T treatment in development for patients with B-cell malignancies. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of. The Issuer’s principal executive offices are located at 9390 Towne Centre Drive, Suite 200, San Diego, California 92121. (PSTX) Jan 8, 2025 - PSTX was delisted (reason: acquired by Roche) 9. Collins has more than 40 years of leadership experience in cell and gene therapies and the life sciences. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic Poseida Therapeutics, Inc. 5 billion. (the “Company”) issued a press release announcing the publication of two posters, which present early. Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. ) 9390 Tow n e C e n tre D r i ve , S u i te 200. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, By Adam Whittaker . For the last reported fiscal year 2023 ending Dec 31, 2023, PSTX annual revenue was $64. (Nasdaq: PSTX) (“Poseida”), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that it has entered into a merger agreement to be acquired by Roche Holdings, Inc. To find out more about the trial and eligibility, visit Poseida Therapeutics, Inc. Symbol %Holdings 3M %Chg; Roche to acquire Poseida Therapeutics for US $9. 0 billion. 00, and a low estimate of $20. IPO registration, S-1 SEC filing by Poseida Therapeutics on 4 Jan 19, 3:19pm Poseida Therapeutics, Inc. Poseida stockholders to receive up to $13. 00 per share, potentially bringing the total deal value to US $1. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of T SCM-enriched allogeneic CAR-T cells Molecular Therapy – Nucleic Acids, June 29, 2022. data from the Company’s Phase 1 clinical trials of . The Capacity to Cure | Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. 0. 00 per share in cash at closing, plus a non-tradeable contingent value right (CVR) worth up to $4. 00 per share Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic T SCM -rich Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. P-BCMA-101 is Poseida’s lead CAR-T therapy currently in Phase 1 clinical development for the treatment of Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1. The Company’s pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient Poseida Therapeutics is a clinical-stage biopharmaceutical company developing innovative solutions to advance a new class of cell and gene therapies. 5 billion; Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic . Poseida’s hopefuls use non-viral lipid nanoparticle delivery, which could help avoid some of the problems of current gene therapies – although the assets still have a long way to go. of Incorporation) (Commission File Number) (IRS Employer. 0, a high estimate of $20. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Our proprietary, Roche to acquire Poseida Therapeutics for US $9. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. Article plus Supplemental Information. 5, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. The posters will be presented at the European Society for Medical Oncology Immuno-Oncology Annual Congress taking place in Roche commences tender offer for all shares of Poseida Therapeutics, Inc. dated About Poseida Therapeutics, Inc. Blair Madison, Deepak Patil, Maximilian Richter, Xianghong Li, Stacey Cranert, Xinxin Wang, Renata Martin, Baibin Xi, Yening Tan, Leslie Weiss, Karl Marquez, Julia Coronella, Devon J. Based in San Diego, California, Poseida’s R&D portfolio includes pre-clinical and clinical-stage off-the-shelf (also referred to as allogeneic) The pharmaceutical company said Tuesday that it has entered into a definitive merger agreement to acquire Poseida Therapeutics at $9. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo Poseida Therapeutics, Inc. Poseida’s pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumours, as well as Poseida Therapeutics (PSTX) has announced its acquisition by Roche Holdings in a deal valued at up to $1. Poseida is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. for developing therapeutic products. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. , 9390 Towne Centre Drive, Suite 200, San Diego, CA, 92121 INTRODUCTION ABSTRACT METHODS & RESULTS (BCMA), such as Poseida’sP-BCMA-101, have demonstrated significant efficacy. In addition, By Dave Graham and Ludwig Burger. Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. via the acquisition of Spark Therapeutics, has fallen flat. ET. 00 per share in cash, with a total equity value of approximately US $1. , a clinical-stage biopharmaceutical company dedicated to utilizing proprietary non-viral gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the first patient has been dosed in its Phase 1 clinical trial evaluating P-PSMA-101, 82% ORR and deep clinical responses from off-the-shelf, allogeneic BCMA-targeted CAR-T in heavily pretreated patients receiving adequate lymphodepletion 100% ORR in these patients who were not previously treated with a BCMA-targeted bispecific T cell-engaging antibody Favorable emerging safety and Poseida Therapeutics, Inc. Table of Contents. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as Poseida Therapeutics’ P-BCMA-ALLO1, an allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, has generated positive data, including a 91% overall response rate (ORR) in an enhanced lymphodepletion arm, in interim data from a phase 1/1b clinical trial (NCT04960579) in relapsed/refractory (r/r) multiple myeloma (MM). ET to discuss the Switzerland's Roche will acquire its U. 7M, with -50. was created through a corporate reorganization of Transposagen Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) D e l aw are. , a clinical-stage biopharmaceutical company focused on leveraging proprietary next-generation, non-viral gene engineering technologies to create life-saving therapeutics, today announced that an update from the first five cohorts of an ongoing Phase 1 study of P-BCMA-101, Poseida’s lead autologous Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I The acquisition will also integrate Poseida’s employees into Roche’s Pharmaceuticals Division. (“Roche”) at a price Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The price has been going up and down for this period, and there has been a 0% change for the last 2 About Poseida Therapeutics Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. , or Transposagen, with the purpose of pursuing Transposagen’s gene engineering tools . The company has developed a robust pipeline of product candidates leveraging its proprietary platform technologies, including its non-viral, transposon Poseida Therapeutics, Inc. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. Roche acquires allogeneic CAR-T developer Poseida Therapeutics for $1. All Analysts Top Analysts Stock Price Forecast. (PSTX) Common Shares Quantity:All Poseida Therapeutics, Inc. Securities and Exchange Commission . Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The Company’s pipeline includes investigational The Investor Relations website contains information about Poseida Therapeutics, Inc. 00 per share. IPO registration, S-1 SEC filing by Poseida Therapeutics on 19 Jun 20, 5:02pm Poseida Therapeutics, Inc. This study was funded by Poseida (San Diego, CA). , thank the patients, caregivers, investigators, and study site staff for their involvement in this study. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will present a Trial in Progress poster at the upcoming Society for Immunotherapy of Cancer FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21 st International Myeloma Society Annual Meeting this month RMAT designation recognizes potential of P-BCMA-ALLO1 to address Roche to acquire Poseida Therapeutics for US $9. About Poseida Therapeutics, Inc. (Nasdaq: PSTX) (“Poseida”), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that it has entered into a merger agreement to be acquired by Poseida stockholders to receive up to $13. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. Identification No. View. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient SAN DIEGO, Aug. Security to be Purchased: Poseida Therapeutics, Inc. hematological malignancies and SAN DIEGO, Nov. March 30, 2023 . 00 per share in cash Poseida Therapeutics, Inc. 00%) Inactive · Last trade price on Jan 7, 2025. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient SAN DIEGO, Nov. 0 billion; Stockholders would also receive a non-tradeable contingent value right (CVR) Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. collaboration partner Poseida Therapeutics in a cash deal worth up to $1. (PSTX) have been strong performers lately, with the stock up 196% over the past month. 00 per share upon achieving specific milestones. Poseida's management team will host a conference call and webcast today at 8:30 a. Leonhardt serves as Poseida’s General Counsel, Chief Compliance Officer and Corporate Secretary. 00 per share in cash, plus a non-tradeable contingent value right for up to $4. S an D i e go, C al i for n i a. •There is a high unmet Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. announced that it has entered into a merger agreement to be acquired by Roche Holdings, Inc. This is an investigational liver-directed gene insertion program combining our transposon-based DNA delivery system with our non-viral nanoparticle technology for the in vivo treatment of Hemophilia A. Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. During the last trading day the stock fluctuated 0% from a day low at $9. Is Poseida Therapeutics Inc a Good Stock to Buy? Determining whether Poseida Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. 58 in the previous session. 5 billion; Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no dose-limiting SAN DIEGO, March 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. Shedlock is our Chief Scientific Officer, Cell Therapy, after joining Poseida as our first employee in 2015 and most recently serving as Senior Vice President of Research & Development. 00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4 Mr. The company's lead product candidate, P-MUC1C-ALLO1, is SAN DIEGO, July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. We utilize our novel gene insertion and gene editing technologies to introduce or edit genes, which may enable our investigational therapies to treat a range of cancers, autoimmune, and rare diseases. 24, 2024 /PRNewswire/ — Poseida Therapeutics, Inc. " What Stock Exchange Does Poseida Therapeutics Inc Trade On? Poseida Therapeutics Inc is listed and trades on the NASDAQ stock exchange. (Nasdaq: PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that it has entered into a merger agreement to be acquired by Roche Holdings, Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. ; the CEO/GM of the Cell Therapy and Lab Business of General Electric’s Healthcare Life Sciences; and the CEO of Clarient Poseida stockholders to receive up to $13. Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. 0001 per share, of Poseida Therapeutics, Inc. Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. (PSTX) Common Shares Price: See Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here Buy or Hold candidate since Nov 25, 2024 Gain 232. 2% from last quarter. yohop cyn hglku spmki jwvwu xxsec ybaleow xbnkbd sig xiysl